Marlies is an Assistant Professor at the University of Pittsburgh, US. She received her PhD in the Molecular Cell Biology and Oncology (MCBO) graduate program from the Medical University of Innsbruck, Austria in the lab of Prof. Gottfried Baier where her work focused on mechanisms of how Th17 cells mediate autoimmunity. Dr. Meisel did her postdoctoral training with Prof. Bana Jabri at the University of Chicago, US. Supported by the FWF Erwin Schrödinger Postdoctoral Fellowship and the CCFA Chron’s and Colitis Research Fellowship Award Dr. Meisel set out to better understand the complex interplay between commensal microbes with the mucosal and systemic immune system in intestinal inflammatory disorders and cancer. She deciphered that the pro-inflammatory cytokine interleukin-15 (IL-15), relevant in inflammatory bowel disease, changes the microbial metabolic profile and thus renders the host more susceptible to colitis. Furthermore, she uncovered that microbial-induced IL-6 drive pre-leukemic myeloid cell proliferation in a mouse model of myeloid cancer. In her own laboratory, Dr. Meisel continues to explore mechanisms of how the microbiota modulates systemic immunity during autoimmunity and cancer. Marlies is especially interested in uncovering mechanisms of how the gut-distal tissue microbiome and its released metabolites tune immune responses including cytokine effector functions that affect the etiopathogenesis of autoimmunity and cancer.
Oral Presentation at Cytokines 2023 in Athens, Greece:
Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment
For more details about the Regeneron Awards and former Milstein Young Investigator Awards, please click here.